Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
6,848
6,152
5,252
5,517
5,777
5,347
Crecimiento de los Ingresos (YoY)
26%
17%
-5%
-5%
8%
9%
Costo de los ingresos
1,823
1,752
1,707
1,674
1,438
1,363
Utilidad bruta
5,025
4,400
3,545
3,843
4,339
3,984
Venta, General y Administración
2,565
2,335
1,798
1,737
1,556
1,421
Investigación y Desarrollo
1,852
1,781
1,630
1,670
1,629
1,569
Gastos de Operación
3,205
3,552
3,031
3,164
3,019
2,888
Otras Ingresos (Gastos) No Operativos
--
-10
-12
-5
-3
-1
Ingreso antes de impuestos
1,510
1,163
441
511
1,226
880
Gasto por Impuesto a la Renta
178
98
98
91
170
119
Ingreso Neto
1,332
1,065
343
418
1,058
732
Crecimiento de la Utilidad Neta
455%
211%
-18%
-60%
45%
-8%
Acciones en Circulación (Diluidas)
194.25
194.54
195.19
194.83
194.17
189.02
Cambio de Acciones (YoY)
0%
0%
0%
0%
3%
1%
EPS (Diluido)
6.86
5.47
1.75
2.15
5.43
3.87
Crecimiento de EPS
459%
212%
-18%
-60%
40%
-8%
Flujo de efectivo libre
1,185
920
445
748
1,060
732
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
73.37%
71.52%
67.49%
69.65%
75.1%
74.5%
Margen de operación
26.57%
13.78%
9.78%
12.3%
22.84%
20.49%
Margen de beneficio
19.45%
17.31%
6.53%
7.57%
18.31%
13.68%
Margen de flujo de caja libre
17.3%
14.95%
8.47%
13.55%
18.34%
13.68%
EBITDA
2,456
1,489
1,205
1,268
1,643
1,450
Margen de EBITDA
35.86%
24.2%
22.94%
22.98%
28.44%
27.11%
D&A para EBITDA
636
641
691
589
323
354
EBIT
1,820
848
514
679
1,320
1,096
Margen de EBIT
26.57%
13.78%
9.78%
12.3%
22.84%
20.49%
Tasa de Impuesto Efectiva
11.78%
8.42%
22.22%
17.8%
13.86%
13.52%
Estadísticas clave
Cierre Anterior
$165.1
Precio de apertura
$166.63
Rango del día
$166.63 - $168.58
Rango de 52 semanas
$71.15 - $167.91
Volumen
2.5K
Volumen promedio
24.8K
EPS (TTM)
3.99
Rendimiento de dividendos
--
Cap. de mercado
$63.8B
¿Qué es UCB S.A.?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.